Artemis One Health



Several studies have been conducted over the past decades attempting to unravel the pathogenesis of this deadly disease, however with limited success. New knowledge on the mechanisms of the rabies virus life-cycle and interaction with the host is needed to identifying clinically applicable therapeutic leads, in search of rational intervention strategies. ASKLEPIOS ( brings together eight partners from the Netherlands, The United Kingdom, Czech Republic, Poland, Hungary and Belgium, with unique expertise and resources.

The project objectives are to:

  1. Identify molecules that inhibit rabies virus replication.
  2. Identify molecules that inhibit detrimental host responses to rabies virus infection.
  3. Show whether opening the blood-brain-barrier improves treatment efficacy.
  4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective.

Artemis One Health is involved in the testing of therapeutic candidates, and in the development of innovative drug-delivery systems. Artemis One Health is also work-package leader for the validation of combination therapy.

Status: Finished


ASKLEPIOS (602825) is an innovation research project funded by the EU FP7 program HEALTH.2013.2.3.4-1 – Neglected infectious disease of Central and Eastern Europe FP7-HEALTH-2013-INNOVATION-1.



Erasmus Medical Centre Rotterdam (NL)

The Secretary of State for Environment, Food and Rural Affairs (UK)

Faculty of Veterinary Sciences Bupadest (CZ)

National Veterinary Research Institute of the Polish Ministry of Agriculture and Rural Development (PL)

Szent Istvan Egyetem (HU)

Centre for Agricultural Research of the Hungarian Academy of Sciences (HU)

Institute Pasteur (FR)

Katholieke Universiteit Leuven (BE)

Artemis One Health Research BV (NL)